

This is a repository copy of *Hematological consequences of malaria in mice previously treated for visceral leishmaniasis*.

White Rose Research Online URL for this paper:

<https://eprints.whiterose.ac.uk/185112/>

Version: Published Version

---

**Article:**

Rani, Gulab Fatima, Ashwin, Helen, Brown, Najmeeyah et al. (2 more authors) (2021) Hematological consequences of malaria in mice previously treated for visceral leishmaniasis. Wellcome Open Research. 83. ISSN 2398-502X

<https://doi.org/10.12688/wellcomeopenres.16629.2>

---

**Reuse**

This article is distributed under the terms of the Creative Commons Attribution (CC BY) licence. This licence allows you to distribute, remix, tweak, and build upon the work, even commercially, as long as you credit the authors for the original work. More information and the full terms of the licence here:

<https://creativecommons.org/licenses/>

**Takedown**

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk) including the URL of the record and the reason for the withdrawal request.



RESEARCH ARTICLE

**REVISED** Hematological consequences of malaria in mice previously treated for visceral leishmaniasis [version 2; peer review: 2 approved]

Gulab Fatima Rani <sup>1</sup>, Helen Ashwin<sup>1</sup>, Najmeeyah Brown<sup>1</sup>, Ian S. Hitchcock <sup>2</sup>, Paul M. Kaye <sup>1</sup>

<sup>1</sup>Hull York Medical School, University of York, UK, York, N. Yorks, Yo10 5DD, UK

<sup>2</sup>Department of Biology, University of York, UK, York, N. Yorks, Yo10 5DD, UK

**V2** First published: 16 Apr 2021, 6:83  
<https://doi.org/10.12688/wellcomeopenres.16629.1>  
 Latest published: 18 Jun 2021, 6:83  
<https://doi.org/10.12688/wellcomeopenres.16629.2>

### Abstract

**Background:** Polyparasitism is commonplace in countries where endemicity for multiple parasites exists, and studies in animal models of coinfection have made significant inroads into understanding the impact of often competing demands on the immune system. However, few studies have addressed how previous exposure to and treatment for one infection impacts a subsequent heterologous infection.

**Methods:** We used a C57BL/6 mouse model of drug-treated *Leishmania donovani* infection followed by experimental *Plasmodium chabaudi* AS malaria, focusing on hematological dysfunction as a common attribute of both infections. We measured parasite burden, blood parameters associated with anemia and thrombocytopenia, and serum thrombopoietin. In addition, we quantified macrophage iNOS expression through immunohistological analysis of the liver and spleen.

**Results:** We found that the thrombocytopenia and anemia that accompanies primary *L. donovani* infection was rapidly reversed following single dose AmBisome® treatment, along with multiple other markers associated with immune activation (including restoration of tissue microarchitecture and reduced macrophage iNOS expression). Compared to naive mice, mice cured of previous *L. donovani* infection showed comparable albeit delayed clinical responses (including peak parasitemia and anemia) to *P. chabaudi* AS infection. Thrombocytopenia was also evident in these sequentially infected mice, consistent with a decrease in circulating levels of thrombopoietin. Architectural changes to the spleen were also comparable in sequentially infected mice compared to those with *Plasmodium* infection alone.

**Conclusions:** Our data suggest that in this sequential infection model, previously-treated *L. donovani* infection has limited impact on the

### Open Peer Review

Approval Status

	1	2
<b>version 2</b> (revision) 18 Jun 2021	 view	
	↑	
<b>version 1</b> 16 Apr 2021	? view	 view

1. **Yasuyuki Goto** , The University of Tokyo, Tokyo, Japan
2. **Breanna M. Scorza** , University of Iowa, Iowa City, USA

Any reports and responses or comments on the article can be found at the end of the article.

subsequent development of Plasmodium infection, but this issue deserves further attention in models of more severe disease or through longitudinal population studies in humans.

### Keywords

visceral leishmaniasis, malaria, mouse models, hematology, chemotherapy, coinfection

**Corresponding authors:** Ian S. Hitchcock ([ian.hitchcock@york.ac.uk](mailto:ian.hitchcock@york.ac.uk)), Paul M. Kaye ([paul.kaye@york.ac.uk](mailto:paul.kaye@york.ac.uk))

**Author roles:** Rani GF: Conceptualization, Data Curation, Formal Analysis, Investigation, Methodology, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing; Ashwin H: Formal Analysis, Investigation; Brown N: Investigation; Hitchcock IS: Conceptualization, Funding Acquisition, Methodology, Project Administration, Resources, Supervision, Writing – Review & Editing; Kaye PM: Conceptualization, Data Curation, Funding Acquisition, Methodology, Project Administration, Resources, Supervision, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing

**Competing interests:** No competing interests were disclosed.

**Grant information:** This work was funded by a Wellcome Trust Senior Investigator Award (to PMK: WT104726), a British Heart Foundation grant (to ISH: PG/16/26/32099) and by a scholarship to GR from Khyber Medical University/Higher Education Commission, Pakistan.

*The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.*

**Copyright:** © 2021 Rani GF *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**How to cite this article:** Rani GF, Ashwin H, Brown N *et al.* **Hematological consequences of malaria in mice previously treated for visceral leishmaniasis [version 2; peer review: 2 approved]** Wellcome Open Research 2021, 6:83 <https://doi.org/10.12688/wellcomeopenres.16629.2>

**First published:** 16 Apr 2021, 6:83 <https://doi.org/10.12688/wellcomeopenres.16629.1>

**REVISED Amendments from Version 1**

Version 2 provides additional discussion to address reviewers' questions, clarifies some experimental details and includes a revised Figure 4C with re-labelled Y axis. Minor editing errors have been corrected.

**Any further responses from the reviewers can be found at the end of the article**

## Introduction

In countries where multiple parasites are endemic, polyparasitism – the presence of multiple species of parasites in the same individual – is commonplace. Polyparasitism involving various bacterial, viral and parasitic diseases, including malaria, schistosomiasis and other helminthoses, tuberculosis, and HIV is well documented and can lead to synergistic or antagonistic clinical and immunological effects<sup>1-4</sup>. In experimental models of leishmaniasis, a number of previous studies have also addressed the issue of coinfection. For example, in mice coinfecting with *Leishmania donovani* and *Schistosoma mansoni*, granulomatous inflammation in the liver progressed normally, although *L. donovani*-induced granulomas found nested within the granulomas induced by *S. mansoni* eggs failed to develop normally<sup>5</sup>. Experimental visceral leishmaniasis (VL) was also shown to confer enhanced protection against *Streptococcus pneumoniae* sepsis<sup>6</sup>. Similarly, in experimental models of malaria as a concurrent or superimposed infection, aggravating or protective responses were noticed<sup>7-10</sup>, suggestive of the role of immune dysregulation.

In areas where human VL and malaria are endemic, the prevalence of coinfection can be high. For example, one cross-sectional retrospective study in Sudan indicated that up to 31% of hospitalized VL cases had concomitant malaria<sup>11</sup>. Similarly, cross-sectional studies in Ethiopia provided a prevalence estimate for coinfection of 2–4%<sup>12,13</sup>. In contrast to the wealth of data on coinfection, the question of whether previous history of VL impacts on subsequent episodes of malaria has not been documented. Similarly, risk factors for VL recurrence have been identified including persistent splenomegaly, poor hematological response and VL/HIV coinfection<sup>14-17</sup>. In regions where malaria is common, exposure of previously-treated VL patients to *Plasmodium* may occur early after discharge, but whether these risk factors for VL recurrence are also risk factors for malaria or other secondary infections is currently unknown.

A number of recent studies suggest that primary systemic infections may have significant long-term impacts on immunological and hematological health. For example, experimental VL has been shown to impact hematopoiesis by driving premature hematopoietic stem cell exhaustion and emergency hematopoiesis may impact myeloid cell function<sup>18-21</sup>. Similarly, dysfunctional medullary erythropoiesis leading to anemia has also been reported in experimental VL<sup>22</sup>. Immunosuppression due to dysregulated immune responses, lack of early

diagnosis and unavailability of effective treatment could make these patients more at risk of developing concomitant or sequential infections.

Here, we describe a study aimed at addressing the question of whether mice infected with *L. donovani* and then treated with an effective therapeutic regimen (AmBisome®) have altered clinical and parasitological outcomes to a subsequent *Plasmodium chabaudi* (AS) infection. We focus on two aspects of immune dysfunction associated with both primary VL and malaria, namely changes in tissue architecture and hematological profile.

## Methods

### Ethical approval

Ethical approval for the study was obtained from the Animal Welfare and Ethical Review Board of the Department of Biology, University of York, York. All procedures were performed under the authority of a UK Home Office Project License (P49487014). All efforts were made to ameliorate harm by adherence to defined clinical endpoints (including physical and clinical condition) and daily monitoring for any unexpected behaviour. No unexpected adverse events were recorded during this study.

### Sample

C57BL/6 mice bred and maintained at the Biological Services Facility (BSF), University of York were originally sourced from Envigo (Huntingdon, UK). Genetic profiling of mice from the colony using microsatellite markers was conducted at Surrey Diagnostics Ltd (Cranleigh, UK), confirming identity to C57BL/6J at 27 microsatellite markers. Two mice (of four tested) had an additional allele at marker 138 (192bp) one mouse had an additional allele at marker 134 (112bp) and two mice had an additional allele at marker 144 (195bp). Mice were kept in individual ventilated cages at 20–21°C and 56% humidity under specific pathogen-free (SPF) conditions (FELASA 67M and 51M) and provided with food and water *ad libitum* and with cage enrichment. Mice included in experiments were six-eight week old females, of excellent health status and that had not been subject to any genetic manipulation or previous regulated procedures. There were no formal exclusion criteria. To estimate sample size, we used data from Hewitson *et al.*<sup>23</sup> for hemoglobin (Hb) concentration and malaria parasitemia<sup>24</sup>. A sample size of 5 mice per group provides >80% power to detect a 20–25% change when comparing *Leishmania*-infected / drug treated mice with uninfected mice or comparing malaria single-infected mice with sequentially infected mice.


**Procedures.** For *L. donovani* infections, mice were infected once with  $3 \times 10^7$  amastigotes of an Ethiopian strain of *L. donovani* (LV9) via the intravenous route without anesthesia, and infection allowed to proceed for 28 days prior to any subsequent treatment. As required, *L. donovani*-infected mice were treated with a single dose of AmBisome® (8mg/kg, intravenously, resuspended in sterile 5% dextrose in distilled water; Gilead Sciences International, Ltd, Cambridge, UK) at day 28 post infection (p.i.). To assess treatment response in

*L. donovani*-infected mice, groups of mice were killed at d28 post infection (p.i.) i.e. prior to AmBisome® treatment and at weeks 1, 2, 3 and 4 post AmBisome® treatment (see Figure 1A for schematic representation). Two independent experiments involving single *L. donovani* infection followed by drug treatment were performed.

Malaria infection was established by injection of  $1 \times 10^5$  infected red blood cells (iRBCs) of the non-fatal *P. chabaudi* AS strain (herein referred to as *P. chabaudi*) via the intravenous route without anaesthesia. Control, *L. donovani* and *Plasmodium* infected mice were kept under a strict 12-hour light-dark cycle to maintain the *Plasmodium* circadian rhythm that is critical for the progression of this infection. For sequential infection, *L. donovani*-infected mice treated once with AmBisome® as above were rested for four weeks before *Plasmodium* infection. These mice (designated as VTM mice) were compared to mice with *Plasmodium* infection only (M mice) and to age-matched uninfected control mice

(C mice), *L. donovani*-infected mice that did not receive AmBisome® (VU mice) and AmBisome®-treated *L. donovani*-infected mice not infected with *Plasmodium* (VT). To assess outcomes in sequential infection, mice were sampled for blood counts at d28 p.i. with *L. donovani* and 4 weeks after AmBisome® treatment and for blood counts and parasitemia at days 5, 7, 9, 11, 13, 15 and 18 post *P. chabaudi* infection. Mice in all groups were killed at day 18 p.i. with *P. chabaudi* (see Figure 4A for schematic representation). A single sequential infection experiment was conducted.

In each experiment, mice were randomly allocated (using Rand function in Microsoft Excel or by drawing lots and ear tagging) to their respective treatment groups. Downstream analysis of blood and tissue was performed blind to treatment group. Randomization and blinding was performed by members of the research team not involved in subsequent analysis. All animals were visually inspected daily for signs of ill health and were within accepted humane endpoints (loss of



**Figure 1. Recovery of red blood cell parameters in drug-treated *L. donovani* infected mice.** **A**) C57BL/6 mice were infected with  $3 \times 10^7$  LV9 amastigotes intravenously (i.v.) followed by treatment with a single intravenous (i.v.) dose (8mg/kg) of AmBisome® at d28 p.i. All mice were bled via lateral tail vein for blood count analysis at the times indicated. **B–E**) Hemoglobin (Hb; **B**), Hematocrit (Hct; **C**), RBC count (**D**) and red cell distribution width (RDW; **E**) were determined on uninfected control and AmBisome® treated mice at d0, d28 p.i. and weekly post-Rx for four weeks. Data are pooled from two independent experiments with  $n=16$  control mice and  $n=19$  LV9 infected/drug-treated mice at d0, d28 and week1,  $n=13$  control and  $n=14$  treated mice at week 2,  $n=10$  control and  $n=10$  treated mice at week 3,  $n=5$  control and  $n=7$  treated mice at week 4. Data analysed using unpaired t test comparing mean  $\pm$  SD of uninfected control vs drug-treated mice at each time-point, \*,  $p < 0.05$ ; \*\*,  $p < 0.01$ ; \*\*\*,  $p < 0.001$ ; \*\*\*\*,  $p < 0.0001$ .



>20% body weight, piloerection, lethargy). Mice were killed by Home Office approved methods of CO<sub>2</sub> inhalation or overdose of inhaled anesthetic (Isoflurane) followed by cervical dislocation at d18 after *Plasmodium* infection.

### Outcome measures

#### Determination of parasite burden

*Leishmania* parasite burden was determined post-mortem and calculated from counts of Giemsa-stained tissue impression smears and is presented as Leishman-Donovan units (LDUs), where LDU = number of amastigotes/1000 cell nuclei x organ weight (grams). Parasite burdens were determined at the times indicated above. *P. chabaudi* parasitemia was calculated from Giemsa-stained blood smears, using blood sampled at the times given above, where percentage parasitemia = number of iRBCs/total RBCs counted x 100%.

#### Blood collection and analysis

Complete blood count (CBC) analysis was performed using a scil Vet abc Plus+ blood counter (scil animal care company, Dumfries, Scotland, UK) on blood samples collected in EDTA-coated tubes (Microvette CB300 EDTA, Sarstedt, Germany).

The blood parameters analysed includes platelet count, mean platelet volume (MPV), hemoglobin (Hb), Red blood cells (RBC) count, hematocrit (Hct), red blood cell indices (mean cell volume; MCV, mean cell hemoglobin; MCH, mean cell hemoglobin concentration; MCHC, red cell distribution width; RDW), total white blood cell count (WBC) and individual white blood cell counts (neutrophil count, lymphocyte count, eosinophil count, monocyte count).

#### Estimation of circulating thrombopoietin (TPO) levels

Unbound circulating TPO levels were measured in serum samples of experimental and control mice at week 1, 2, 3, 4 post-Rx and d18 post-*Plasmodium* infection, using a Mouse Thrombopoietin Quantikine ELISA Kit (MTP100; R & D systems, Minneapolis, MN, USA) as per manufacturer's guidelines. Some samples were omitted from TPO analysis due to assay limitations.

#### Tissue histology

Livers and spleens of infected and control mice were harvested post-mortem at the end of each experiment, as above, and embedded in cryomolds using OCT Tissue-Tek and snap frozen on dry ice. Tissues were kept at -80°C until needed for further processing. Cryo-embedded tissue sections were cut at a thickness of 8–10µm using CM1900 cryostat (Leica Microsystems, Wetzlar, Germany) and allowed to air dry prior to staining. Tissue sections were fixed with ice-cold acetone for 5 minutes followed by staining with Harris Haematoxylin stain for 10 minutes. Slides were rinsed thoroughly in running water followed by staining with 0.5% Eosin in 95% ethanol. Slides were washed in running tap water and then processed through ethanol solutions for mounting. Staining was carried out at room temperature (RT). Slides were coverslipped with Depex mounting medium (SLS, Nottingham, UK) and left to

dry at RT. Images were captured using an AxioScan.Z1 slide scanner (Zeiss, Oberkochen, Germany) at 20x resolution.

#### Immunohistochemistry

Cryo-embedded livers and spleens were sectioned as described above and fixed in ice-cold acetone for 5 minutes after marking the tissue outlines with ImmEDGE™ Hydrophobic Barrier pen (Vector Laboratories Ltd., Peterborough, UK). Slides were washed with wash buffer (0.05% w/v bovine serum albumin; BSA (Sigma-Aldrich, USA) in sterile 1x phosphate-buffered saline (PBS)) followed by blocking with dilution buffer (5% serum in wash buffer) for 30 minutes at RT. Liver sections were incubated with F4/80 AF647 (Host: Rat, Clone: BM8, Dilution: 1:200, Cat no: 123122, BioLegend) for Kupffer cells and/or unconjugated anti-TPO antibody (Host: Rabbit, Clone: EPR14948, Dilution: 1:100, Cat no: ab196026, Abcam) for TPO-producing hepatocytes while spleen sections were stained with F4/80 AF647, CD169 AF488 (Host: Rat, Clone: 3D6.112, Dilution: 1:200, Cat no: 142419, BioLegend) and unconjugated SIGNR1 (Host: Armenian hamster, Clone: eBio22D1 (22D1), Dilution: 1:50, Cat no: 14-2093-82, eBiosciences) for RP macrophages, marginal metallophilic macrophages (MMM) and marginal zone macrophages (MZM) respectively, for 45 minutes at RT. Slides were washed three times in wash buffer (3–5 minutes per wash with shaking). Liver sections were then incubated with goat anti-rabbit AF488 secondary antibody (Host: Goat, Clone: Polyclonal, Dilution: 1:200, Cat no: A-11034, Invitrogen) and spleen sections with goat anti-hamster AF546 secondary antibody (Host: Goat, Clone: Polyclonal, Dilution: 1:200, Cat no: A-21111, Invitrogen) for 30 minutes at RT. Slides were washed three times with wash buffer and twice with 1x PBS. All the tissue sections were counterstained with a nuclear stain, 4',6-diamidino-2-phenylindole (DAPI; 1µg/ml in PBS) for 5 minutes. Slides were washed thoroughly with PBS and mounted with coverslips using ProLong® gold antifade mountant (Thermo Fisher Scientific, UK). Images were captured using AxioScan.Z1 Slide scanner (Zeiss, Oberkochen, Germany) at 20x resolution using Zen software (Zeiss, Oberkochen, Germany). Data were collected from 1–3 sections per mouse and pooled for analysis and processed for segmentation analysis using [StrataQuest](#) image analysis software (TissueGnostics, Vienna, Austria). Segmentation analysis was done by identifying cell nuclei and creating outlines around the cells based on the immunofluorescent staining. Cells with high auto-fluorescence were excluded from the final analysis. A similar strategy for segmentation analysis could be conducted in freely available open access software (e.g. [Fiji ImageJ](#)).

#### Statistical analysis

Data were analysed and figures constructed using [GraphPad Prism 8](#) software (GraphPad Software, San Diego, CA). Alternative open access statistical analysis and graph making packages could be used (e.g. [R](#)). Parametric or non-parametric statistical tests were applied depending on the distribution of data and data represented as mean ± SD and median with quartiles respectively. Unpaired t test was used when comparing mean of two groups while ANOVA with post-hoc Tukey's or Dennett's and Kruskal Wallis with post-hoc Dunn's tests were used when comparing more than two groups. A p-value

of less than 0.05 was taken as significant, expressed as, \* (< 0.05), \*\* (< 0.01), \*\*\* (< 0.001) and \*\*\*\* (< 0.0001).

## Results

### Restoration of hematological profile and tissue microarchitecture in AmBisome®-treated *L. donovani*-infected C57BL/6 mice

We have previously reported that seven days after single dose (8mg/kg) AmBisome® treatment, BALB/c mice show effective clearance of systemic parasite load and rapid resolution of the hepatic granulomatous response, but with an incomplete restoration of transcriptional homeostasis<sup>25</sup>. We have also found that by four weeks after single dose (8mg/kg) AmBisome® treatment of C57BL/6 mice, there is complete restoration of platelet count, mean platelet volume (MPV), hepatomegaly, circulating and tissue TPO levels but only a partial restoration of splenomegaly<sup>26</sup>. We therefore extended these key findings in the C57BL/6 model of VL to investigate other hematological and architectural changes post-treatment (Rx), using the same drug dosage and for a follow-up period of four weeks (Figure 1A). In *L. donovani* infected C57BL/6 mice, restoration of blood parameters (Hb, hemoglobin; HCT, hematocrit; RBC, red blood cell count) had begun to occur by week one post-Rx and reached the normal range for all parameters measured by four weeks post-Rx (Figure 1B–D)<sup>24</sup>. Of note, red cell distribution width (RDW) increased during infection and continued to do so for two weeks post-Rx before it then returned to baseline levels (Figure 1E), suggesting that erythrocytes of variable shapes and sizes are a feature of chronic *L. donovani* infection that recovers after parasite clearance. Changes to leucocytes were unremarkable during primary VL and post-Rx (extended data 1<sup>24</sup>).

No parasites were found on the Giemsa-stained tissue impression smears over the four-week follow-up, in either spleen or liver, and both tissues displayed signs of restoration of homeostasis. Hematoxylin and eosin (H&E) staining of liver sections confirmed these findings with a reduction in the sizes of hepatic granulomas and restoration of normal liver architecture (Figure 2A). A decrease in the number of F4/80<sup>+</sup> macrophages provided additional evidence of architectural restoration in the liver (Figure 2B). Furthermore, a reduction in the number of F4/80<sup>+</sup>iNOS<sup>+</sup> cells, both inside and outside the resolving hepatic granulomas was observed (Figure 2C–D), suggesting a decline in hepatic macrophage activation status.

A partial recovery of macrophages in the splenic marginal zone, including marginal zone macrophages (MZM) and marginal metallophilic macrophages (MMM) and a reduction in red pulp (RP) macrophages was also indicative of some restoration of splenic microarchitecture post-Rx (Figure 3A). A progressive reduction in F4/80<sup>+</sup> RP macrophages and trend towards slow restoration of CD169<sup>+</sup> MMM and SIGNR1<sup>+</sup> MZM was seen over a period of four weeks post-Rx (Figure 3B–D). A trend towards an increase in the number of iNOS<sup>+</sup> splenic RP macrophages was also observed for the initial three weeks post-Rx followed by a sharp decline at four weeks post-Rx (Figure 3E), suggestive of a transient increase in splenic

macrophage activation associated with parasite death in this organ, with some residual activation remaining at four weeks post Rx.


In summary, four weeks after a curative dose of AmBisome®, C57BL/6 mice recovered from many of the salient features of primary experimental VL, but as with humans discharged following treatment, showed some signs of persistent splenic pathology. No unexpected adverse effects were observed in either experimental or control groups throughout the course of experiment.

### Clinical outcome of sequential *P. chabaudi* infection in mice previously infected and cured from *L. donovani* infection

To determine whether previous *L. donovani* infection and AmBisome® treatment altered the outcome of primary *P. chabaudi* infection, we compared sequentially infected mice (VTM) with mice receiving only primary infection with *P. chabaudi* (M) as indicated in Figure 4A. In addition to naïve control mice (C), additional control groups of mice included: i) mice infected and cured of *L. donovani* infection but without *Plasmodium* infection (VT) to ascertain whether spontaneous VL relapse occurred, and ii) mice infected with *L. donovani* but untreated (VU) to monitor natural progression of the primary infection (Figure 4A).

Parasitemia was determined over 18 days in all *P. chabaudi*-infected mice (M, VTM). Although the peak *P. chabaudi* parasitemia was equivalent in M and VTM mice, time to peak parasitemia was delayed by two days in VTM mice (Figure 4B). This delay in parasitemia was mirrored in a delayed loss of body weight in VTM compared to M mice (Figure 4C). At day 18 p.i., *P. chabaudi* splenomegaly was similar between M and VTM mice (Figure 4D) but hepatomegaly was minimal in both groups (Figure 4E). We also determined whether sequential *P. chabaudi* infection led to a relapse of primary VL, by comparing *L. donovani* tissue parasite load in VU, VT and VTM mice (Figure 4F). No differences were observed in *L. donovani* load between VT and VTM mice, indicating that subsequent *Plasmodium* infection did not trigger relapse of *L. donovani* infection. In comparison to VT mice, small numbers of *Leishmania* amastigotes were detectable in the liver and to a greater extent the spleen of VU mice, indicative of a low level of persistence of parasites in untreated C57BL/6 mice. Thus, under these experimental conditions, sequential *P. chabaudi* infection did not lead to increased tissue amastigote burden. No unexpected adverse effects were observed in either experimental or control groups throughout the course of experiment.

In VTM mice, we observed a delayed hematological response to malaria as compared to M mice, consistent with the delayed kinetics of the *P. chabaudi* infection. As anticipated<sup>26</sup>, we observed in VTM mice that the thrombocytopenia associated with primary *L. donovani* infection was fully reversed by four weeks post AmBisome® treatment. Delayed onset of thrombocytopenia after *P. chabaudi* infection was observed in



**Figure 2. Restoration of hepatic microarchitecture in drug-treated *L. donovani* infected mice.** **A**) H & E-stained liver sections of (i) uninfected control, (ii) d28, (iii) wk1, (iv) wk2, (v) wk3, (vi) wk4 post-Rx mice show the recovery of normal hepatic microarchitecture, scale bar; 100 $\mu$ m. **B**) Number of F4/80<sup>+</sup> cells after treatment with AmBisome®, determined by segmentation analysis. Data are amalgamated from two independent experiments using 23 mice, with n=3 uninfected controls (Expt. 1), n=5 d28 infected (Expt. 2) and n=3-5 treated mice per time-point (Expt. 1). Data are expressed as median with quartiles and analysed using non-parametric Kruskal-Wallis with Dunn's post-hoc test, \*, p < 0.05; \*\*, p < 0.01. **C** and **D**) Number of iNOS<sup>+</sup> F4/80<sup>+</sup> cells per unit area inside (**C**) and outside (**D**) hepatic granulomas, determined by segmentation analysis in StrataQuest. Data are derived from n=3 uninfected control mice, n=5 d28 infected mice and n=3 treated mice at weeks 1-4, as above. Data shown as median with quartiles and were analysed using non-parametric Kruskal-Wallis test with Dunn's post-hoc test, \*, p < 0.05; \*\*, p < 0.01.


these mice as compared to M mice (Figure 5A), though the rate of thrombocytopenia progression and severity were similar in both groups. The increase in platelet volume (MPV) was also delayed in VTM mice as compared to M (Figure 5B). Similarly, *Plasmodium*-induced anemia was delayed in the VTM group in comparison to M group, assessed by RBC count, Hb and Hct (Figure 5C-E). Other red cell indices MCV, MCH, MCHC and RDW showed a similar pattern in both groups.

Leucopenia and leucocytosis both are reported as a feature of *Plasmodium* infection<sup>27,28</sup> and total WBC count began to rise with increasing parasitemia in M group mice and at a later

time in VTM mice (Figure 5F). Our data show an increase in total WBC count after d13 of malaria when parasitemia started to decline (Figure 5F). Together these data suggest that hematological changes in the peripheral blood are sensitive to the delayed rise in parasitemia observed in VTM mice. No significant difference in any of the blood parameters was observed in control groups (C, VT). A slow recovery of blood counts was seen in VU mice suggestive of natural self-resolution of infection in mice (extended data 2<sup>24</sup> and 29).

Quantitative immunohistochemistry analysis, on mice killed 18 days after *P. chabaudi* infection, was used to examine





**Figure 3. Restoration of splenic microarchitecture in drug-treated *L. donovani* infected mice.** **A** Spleen sections of (i) uninfected control, (ii) d28, (iii) wk1, (iv) wk2, (v) wk3, (vi) wk4. post-Rx mice were stained with macrophage markers, DAPI (Blue); nuclei, F4/80 (Red); RP macrophages, CD169 (Green) and SIGNR1 (Magenta) for MMM and MZM respectively, scale bar; 100 $\mu$ m. **B-D** The number of F4/80<sup>+</sup> RP macrophages (**B**), CD169<sup>+</sup> MMM (**C**) and SIGNR1<sup>+</sup> MZM (**D**) after treatment with AmBisome® was determined by segmentation analysis. Data are amalgamated from two independent experiments with n=14 uninfected control (Expt. 1 and 2), n=5 d28 infected (Expt. 2) and n=3-5 treated mice per time-point post-Rx (Expt. 1). Data shown as median with quartiles and were analysed using non-parametric Kruskal-Wallis test with Dunn's post-hoc test, \*, p < 0.05; \*\*\*, p < 0.001. **E** The number of iNOS<sup>+</sup> F4/80<sup>+</sup> cells per unit area was determined by segmentation analysis. Data are representative of n=3 uninfected control mice, n=5 d28 infected mice and n=3 treated mice at weeks 1-4 post-Rx, as above. Data shown as median with quartiles and were analysed using non-parametric Kruskal-Wallis test with Dunn's post-hoc test, \*, p < 0.05.


whether there were any synergistic or antagonistic effects on splenic architecture between single and sequentially infected mice (Figure 6A). M and VTM mice had similarly reduced numbers of F4/80<sup>+</sup> RP macrophages per unit area compared to VU mice (Figure 6B), not dissimilar to C and VT mice. Additionally, the destruction of the splenic marginal zone was also similar in *Plasmodium*-infected mice. As expected, recovery of CD169<sup>+</sup> MMM appeared to be greater in VT mice at seven weeks post AmBisome® treatment (Figure 6C) compared to at four weeks post treatment (Figure 3C). In contrast, complete restoration of SIGNR1<sup>+</sup> MZM was not observed even at this later time point in VT spleens, and a further reduction was noticed in *Plasmodium*-infected mice (Figure 6D), suggestive of cumulative pathological remodeling.

The architectural changes in the livers of *Plasmodium*-infected mice were consistent with the published literature including the presence of orange-red malaria pigment, hemozoin (Figure 6E). The number of F4/80<sup>+</sup> cells were not significantly

different across treatment groups and controls (Figure 6F). Serum TPO levels were also analysed in all groups of mice, as this has previously been correlated with thrombocytopenia. VT mice had similar serum TPO concentration to C mice, indicative of treatment response and significant restoration of blood homeostasis (Figure 6G). In contrast, VU, VTM and M mice all displayed reduced serum TPO levels, approximating 50% of that seen in C mice (Figure 6G), consistent with the similar levels of thrombocytopenia observed in these mice (Figure 5A and Extended Data 2). Hence, both *L. donovani* and *P. chabaudi* infections reduce TPO levels to a similar extent with no indication of synergistic or antagonistic activity.

## Discussion

Both leishmaniasis and malaria are among the tropical diseases with a huge overlap of geographical and clinical presentation<sup>11,30-33</sup>. The presence of coinfections with VL not only makes it difficult to treat but may also pose a risk of relapse in treated cases<sup>34</sup>. Although VL/HIV coinfection is




**Figure 4. Disease kinetics of *Plasmodium* infection in drug-treated *L. donovani* infected mice. **A**** A cohort of 14 *L. donovani*-infected C57BL/6 mice were randomly allocated to receive single dose of AmBisome® (8mg/kg) at d28 p.i. (n=9) or no treatment (VU; n=5). Four weeks post-Rx, AmBisome®-treated mice were randomly allocated to receive  $1 \times 10^5$  *P. c. chabaudi* (AS) iRBCs intravenously (VTM; n=5) or no *Plasmodium* infection (VT; n=4). Control mice included mice infected only with *P. c. chabaudi* (AS) (M; n=5), *L. donovani*-infected but untreated mice (VU; n=5), and control naïve mice (C; n=4). All mice were kept under strict 12-hour light-dark cycle and monitored regularly for parasitemia, weight loss, blood counts and signs of disease severity. **B** Parasitemia in *Plasmodium*-infected mice (M, VTM) determined from Giemsa-stained blood smears. Data is shown as % body weight compared to day 0. **C** % bodyweight was determined in control (C) and *Plasmodium*-infected (M, VTM) mice at the times indicated. Data were analysed using ANOVA with Dennett's post-hoc test comparing mean  $\pm$  SD of M and VTM groups with C group, \*,  $p < 0.05$ ; \*\*,  $p < 0.01$ ; \*\*\*,  $p < 0.001$ ; \*\*\*\*,  $p < 0.0001$ . **D** and **E**. Post-mortem spleen (**D**) and liver (**E**) weights were determined in control (C, VT, VU) and *Plasmodium*-infected (M, VTM) groups. Data were analysed using ANOVA with Tukey's post-hoc test, \*,  $p < 0.05$ ; \*\*,  $p < 0.01$ . **F** *Leishmania* parasite burden in spleen and liver was determined from Giemsa-stained tissue impression smears of tissues from VT, VU and VTM mice. Data are shown as LDUs. Data were analysed using ANOVA with Tukey's post-hoc test, \*,  $p < 0.05$ .

prevalent and well-studied, there is an increasing incidence of other infections coexisting with VL<sup>11,13,32,33,35</sup>. In this study, we established a model of a sequential *P. chabaudi* infection in a AmBisome®-treated murine VL model to specifically address the question of whether mice previously exposed to *L. donovani* and cured using a first line therapy would differ in their subsequent response to malaria challenge.

As previously documented<sup>25</sup>, *L. donovani*-infected BALB/c mice treated with a single dose of AmBisome® (8mg/kg) at d28 p.i. showed a progressive recovery towards immune homeostasis. Here, we extend our previous study by showing that the resolution of hepatic granulomatous inflammation, imputed from transcriptomic analysis and quantified in H&E-stained

liver sections, is also accompanied by a reduction in the activation status of F4/80<sup>+</sup> hepatic macrophages (predominantly Kupffer cells), measured by iNOS expression. In the spleen, accompanying the reduction in splenomegaly previously reported<sup>25</sup>, we now formally document the partial recovery of populations of marginal zone macrophages and provide evidence for the activation status of splenic macrophages. As expected, based on early studies of repopulation kinetics following clodronate depletion<sup>36</sup>, recovery of MZMs and MMMs was slow and incomplete at four weeks post treatment. One week after AmBisome® treatment, the abundance of red pulp F4/80<sup>+</sup> iNOS<sup>+</sup> macrophages increased significantly. This was in contrast to our previous transcriptomic data that indicated a reduction in overall tissue *Nos2* accumulation



**Figure 5. Hematological changes in response to *Plasmodium* infection in drug-treated *L. donovani* infected mice. A-E** Platelet count (A) mean platelet volume (MPV; B) total RBC count (C) hemoglobin (Hb; D), hematocrit (Hct; E) and total white blood cell count (WBC; F) were determined in *P. c. chabaudi* (AS) infected mice (M), *P. c. chabaudi* (AS) infected mice with previously-treated *L. donovani* infection (VTM) and control mice (C) were determined at the times indicated. All data are representative of a single experiment with  $n=4$  C,  $n=4$  VT,  $n=5$  VU,  $n=5$  M and  $n=5$  VTM mice. Data were analysed using ANOVA with Dennett's post-hoc test comparing mean  $\pm$  SD of M and VTM groups with C group, \*,  $p < 0.05$ ; \*\*,  $p < 0.01$ ; \*\*\*,  $p < 0.001$ ; \*\*\*\*,  $p < 0.0001$ .

at this time point<sup>25</sup>, suggesting that other cell populations also play an important role in iNOS production during active VL. The number of F4/80<sup>+</sup> iNOS<sup>+</sup> cells was maintained over the following two weeks before declining at four weeks to a level that remained above that seen in naïve control mice. This analysis is consistent with a residual level of macrophage activation in the red pulp at the time of malaria challenge in this study and with a previous report which found that activated red pulp macrophages during *L. donovani* infection can have enhanced phagocytic capacity towards heterologous pathogens<sup>6</sup>.


We used these *L. donovani*-infected, drug treated mice to determine whether there was any impact on the subsequent development of a primary *P. chabaudi* infection. Whilst there was a clear delay in the kinetics of all parasitological and clinical parameters measured, including parasitemia, loss of body weight and cytopenia, there was no quantitative differences in the severity of malaria between sequentially infected mice (VTM) and control mice infected only with *P. chabaudi* (M). Histological changes in the liver and spleen of VTM mice were consistent with that expected from a single *P. chabaudi* infection (this report and 37).

Recent attention has been focused on the ability of previous exposure to train the innate immune system for heightened responsiveness on secondary heterologous challenge, so

called trained immunity<sup>38,39</sup>. Trained immunity has been most well-studied in phagocytes exposed to strong agonists of innate pattern recognition receptors such as BCG or  $\beta$ -glucan, and may involve both epigenetic and metabolic reprogramming in the periphery or at the level of bone marrow stem cells<sup>40,41</sup>. Although we have not formally addressed whether *L. donovani* infection can stimulate trained immunity or whether there may be immunological cross reactivity between *Leishmania* and *Plasmodium* impacting the T and / or B cell response, given our current data we feel the most likely explanation for the delay in malaria kinetics is that F4/80<sup>+</sup> iNOS<sup>+</sup> cells in the spleen have enhanced capacity to clear iRBCs<sup>42</sup> and hence the initial parasite load establishing the malaria infection is reduced. Further studies would be required to test this hypothesis formally and/ or to establish a role for either trained immunity or T cell / B cell cross-reactivity following *L. donovani* infection.

A weakness of the current study is that *Plasmodium* infection was initiated by needle challenge using iRBCs, rather than via mosquito bite<sup>43,44</sup>. Hence, it is not possible with this model to ascertain whether changes to the liver microenvironment that remain after cure from VL might impact on the establishment of the exoerythrocytic stages of the malaria life cycle. Whilst we did not see residual iNOS activity in the liver and hepatic granulomatous inflammation had subsided significantly one month after treatment (this report and ref 25), more subtle





**Figure 6. Tissue microarchitectural changes in response to *Plasmodium* infection in drug-treated *L. donovani* infected mice.**

**A)** Spleen sections of (i) C, (ii) VT, (iii) VU, (iv) M and (v) VTM mice killed 18 days post *P. c. chabaudi* (AS) infection (see Figure 4A) were stained with macrophage markers, F4/80 (Red); RP macrophages, CD169 (Green) and SIGNR1 (Magenta). Scale bar; 100µm. **B–D)** Number of F4/80<sup>+</sup> RP macrophages (**B**), CD169<sup>+</sup> MPM (**C**) and SIGNR1<sup>+</sup> MZM (**D**) in indicated groups. Data shown as median with quartiles and were analysed using non-parametric Kruskal-Wallis with post-hoc Dunn's test comparing the median of each group, \*,  $p < 0.05$ ; \*\*,  $p < 0.01$ . **E)** H & E-stained liver images of (i) C, (ii) VT, (iii) VU, (iv) M and (v) VTM mice. Orange-red pigment is hemozoin (\*). **F)** Number of F4/80<sup>+</sup> cells per unit area, determined by segmentation analysis for each mouse group. Data shown as median with quartiles of  $n=4$  C,  $n=4$  VT,  $n=5$  VU,  $n=5$  M and  $n=5$  VTM mice. **G)** Circulating thrombopoietin (TPO) was determined in serum samples of each mouse group by ELISA at the end of the experiment (day 18 post *P. c. chabaudi* (AS) infection). Data show the results of a single experiment with  $n=4$  C,  $n=4$  VT,  $n=3$  VU,  $n=4$  M and  $n=4$  VTM mice. Data shown as mean  $\pm$  SD and were analysed using ANOVA with Tukey's as post-hoc test, \*\*,  $p < 0.01$ ; \*\*\*\*,  $p < 0.0001$ .

changes to hepatic endothelial cells, Kupffer cells or hepatocytes that affect sporozoite invasion and / or exo-erythrocytic schizogony cannot be excluded. In addition, we did not directly examine immune parameters associated with acquired primary resistance to *Plasmodium* or whether any defects associated with previous VL impacted on the generation of memory during primary *Plasmodium* infection. These represent interesting questions that might be addressed in future studies.

In humans, trials of short course AmBisome® treatment in Bangladesh have indicated that residual splenomegaly one month after the initiation of treatment is a risk factor for relapse<sup>45</sup>, mirroring earlier data from patients treated with AmBisome® in India<sup>14</sup> and with sodium stibogluconate and paromomycin in South Sudan<sup>15</sup>. Hence, it seemed reasonable in the absence of other data, and given that in regions of high malaria endemicity patients may be discharged with residual splenomegaly, to evaluate responses to *Plasmodium* infection one month after AmBisome® treatment in this murine model. A majority of malaria cases might, however, be assumed to occur at later times after patients had received treatment

for VL and we cannot exclude the possibility that alternate schedules of sequential infection may lead to differing outcomes. Similarly, the mouse model of VL fails to display the full severity and duration of human VL, both factors that might influence bone marrow function with respect to platelet and erythrocyte production as well as other parameters of immunity to malaria. Studies in the more severe hamster model of VL may be warranted. Whilst a previous study examined coinfection with the cutaneous parasite *Leishmania enriettii* and *P. berghei*<sup>46</sup>, *Plasmodium* infections in the hamster are relatively poorly understood, potentially limiting the value of such a model.

In summary, our data indicate that despite similar impacts on peripheral blood red cell and platelet counts, and evidence for hematological disturbances associated with both malaria and visceral leishmaniasis, we found that sequential infection led only to a delay in primary malaria parasitemia, with minimal impact on other clinical or histopathological features. Although studies in animal models such as the one described have value for mechanistic studies, given the limitations imposed by these models, the question of how infections interact in a sequential manner should be studied in parallel through



longitudinal population-based studies in humans naturally exposed to both pathogens.

## Data availability

### Underlying data

Open Science Framework: Impact of prior visceral leishmaniasis on subsequent malaria infection in mice. <https://doi.org/10.17605/OSF.IO/DSVCP24>

This project contains the following underlying data:

- Sample size calculations Raw data
- [Figure 1](#) Raw data (Recovery of red blood cell parameters in drug-treated *L. donovani* infected mice.)
- [Figure 2](#) Raw data (Restoration of hepatic microarchitecture in drug-treated *L. donovani* infected mice.)
- [Figure 3](#) Raw data Restoration of splenic microarchitecture in drug-treated *L. donovani* infected mice.
- [Figure 4](#) Raw data (Disease kinetics of malaria infection in drug-treated *L. donovani* infected mice).
- [Figure 5](#) Raw data (Hematological changes in response to malaria infection in drug-treated *L. donovani* infected mice).
- [Figure 6](#) Raw data (Tissue microarchitectural changes in response to malaria infection in drug-treated *L. donovani* infected mice).

- Extended data 1 Raw Data (Leucocyte counts in drug-treated *L. donovani* infected mice)
- Extended data 2 Raw data (Hematological changes in the control groups of drug-treated *L. donovani* infected mice)

### Extended data

Open Science Framework: Impact of prior visceral leishmaniasis on subsequent malaria infection in mice. <https://doi.org/10.17605/OSF.IO/DSVCP24>

This project contains the following extended data:

- Extended data 1 (Leucocyte counts in drug-treated *L. donovani* infected mice)
- Extended data 2 (Hematological changes in the control groups of drug-treated *L. donovani* infected mice)

Data are available under the terms of the [Creative Commons Attribution-ShareAlike 4.0 International](#) (CC BY-SA 4.0).

## Acknowledgements

Authors thank the Biological Services Facility (BSF) and Biology Technology Facility for their support in animal husbandry and imaging, respectively. *P. chabaudi* parasites were kindly provided by Dr Jean Langhorne (The Francis Crick Institute London, UK).

## References

1. Gorsch EE, Etienne RS, Medlock J, et al.: **Opposite outcomes of coinfection at individual and population scales.** *Proc Natl Acad Sci U S A.* 2018; **115**(29): 7545–50. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
2. Griffiths EC, Pedersen AB, Fenton A, et al.: **The nature and consequences of coinfection in humans.** *J Infect.* 2011; **63**(3): 200–6. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
3. Briand V, Watier L, Le Hesran JY, et al.: **Coinfection with *Plasmodium falciparum* and *Schistosoma haematobium*: Protective effect of schistosomiasis on malaria in Senegalese children?** *Am J Trop Med Hyg.* 2005; **72**(6): 702–7. [PubMed Abstract](#) | [Publisher Full Text](#)
4. Supali T, Verweij JJ, Wiria AE, et al.: **Polyparasitism and its impact on the immune system.** *Int J Parasitol.* 2010; **40**(10): 1171–6. [PubMed Abstract](#) | [Publisher Full Text](#)
5. Hassan MF, Zhang Y, Engwerda CR, et al.: **The *Schistosoma mansoni* hepatic egg granuloma provides a favorable microenvironment for sustained growth of *Leishmania donovani*.** *Am J Pathol.* 2006; **169**(3): 943–53. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
6. Kirby AC, Beattie L, Maroof A, et al.: **SIGNR1-negative red pulp macrophages protect against acute streptococcal sepsis after *Leishmania donovani*-induced loss of marginal zone macrophages.** *Am J Pathol.* 2009; **175**(3): 1107–15. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
7. Sanches-Vaz M, Temporão A, Luis R, et al.: ***Trypanosoma brucei* infection protects mice against malaria.** *PLoS Pathog.* 2019; **15**(11): e1008145. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
8. Legesse M, Erko B, Balcha F: **Increased parasitaemia and delayed parasite clearance in *Schistosoma mansoni* and *Plasmodium berghei* co-infected mice.** *Acta Trop.* 2004; **91**(2): 161–6. [PubMed Abstract](#) | [Publisher Full Text](#)
9. Su Z, Segura M, Morgan K, et al.: **Impairment of protective immunity to blood-stage malaria by concurrent nematode infection.** *Infect Immun.* 2005; **73**(6): 3531–9. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
10. Graham AL, Lamb TJ, Read AF, et al.: **Malaria-Filaria Coinfection in Mice Makes Malarial Disease More Severe unless Filariasis Infection Achieves Patency.** *J Infect Dis.* 2005; **191**(3): 410–21. [PubMed Abstract](#) | [Publisher Full Text](#)
11. van den Bogaart E, Berkhout MMZ, Nour ABYM, et al.: **Concomitant malaria among visceral leishmaniasis in-patients from Gedarf and Sennar States, Sudan: a retrospective case-control study.** *BMC Public Health.* 2013; **13**: 332. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
12. Ferede G, Diro E, Getie S, et al.: **Visceral Leishmaniasis-Malaria Coinfection and Their Associated Factors in Patients Attending Metema Hospital, Northwest Ethiopia: Suggestion for Integrated Vector Management.** *Malar Res Treat.* 2017; **2017**: 6816913. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
13. Aschale Y, Ayehu A, Worku L, et al.: **Malaria-visceral leishmaniasis coinfection and associated factors among migrant laborers in West Armachiho district, North West Ethiopia: community based cross-sectional study.** *BMC Infect Dis.* 2019; **19**(1): 239. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
14. Burza S, Sinha PK, Mahajan R, et al.: **Risk factors for visceral leishmaniasis relapse in immunocompetent patients following treatment with 20 mg/kg liposomal amphotericin B (Ambisome) in Bihar, India.** *PLoS Negl Trop Dis.* 2014; **8**(1): e2536. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

15. Gorski S, Collin SM, Ritmeijer K, *et al.*: **Visceral leishmaniasis relapse in Southern Sudan (1999–2007): a retrospective study of risk factors and trends.** *PLoS Negl Trop Dis.* 2010; **4**(6): e705.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
16. Kajaia M, Morse DL, Kamkamidze G, *et al.*: **Risk factors for relapse of visceral leishmaniasis in Georgia.** *Trop Med Int Health.* 2011; **16**(2): 186–92.  
[PubMed Abstract](#) | [Publisher Full Text](#)
17. Simão JC, Victória C, Fortaleza CMCB: **Predictors of relapse of visceral leishmaniasis in inner São Paulo State, Brazil.** *Int J Infect Dis.* 2020; **95**: 44–9.  
[PubMed Abstract](#) | [Publisher Full Text](#)
18. Pinto AI, Brown N, Preham O, *et al.*: **TNF signalling drives expansion of bone marrow CD4<sup>+</sup> T cells responsible for HSC exhaustion in experimental visceral leishmaniasis.** *PLoS Pathog.* 2017; **13**(7): e1006465.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
19. Cotterell SE, Engwerda CR, Kaye PM: **Enhanced Hematopoietic Activity Accompanies Parasite Expansion in the Spleen and Bone Marrow of Mice Infected with *Leishmania donovani*.** *Infect Immun.* 2000; **68**(4): 1840–1848.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
20. Abidin BM, Hammami A, Stäger S, *et al.*: **Infection-adapted emergency hematopoiesis promotes visceral leishmaniasis.** *PLoS Pathog.* 2017; **13**(8): e1006422.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
21. Cotterell SE, Engwerda CR, Kaye PM: ***Leishmania donovani* infection of bone marrow stromal macrophages selectively enhances myelopoiesis, by a mechanism involving GM-CSF and TNF- $\alpha$ .** *Blood.* 2000; **95**(5): 1642–51.  
[PubMed Abstract](#) | [Publisher Full Text](#)
22. Preham O, Pinho FA, Pinto AI, *et al.*: **CD4<sup>+</sup> T Cells Alter the Stromal Microenvironment and Repress Medullary Erythropoiesis in Murine Visceral Leishmaniasis.** *Front Immunol.* 2018; **9**: 2958.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
23. Hewitson JP, West KA, James KR, *et al.*: ***Malat1* Suppresses Immunity to Infection through Promoting Expression of Maf and IL-10 in Th Cells.** *J Immunol.* 2020; **204**(11): 2949–60.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
24. Kaye P: **Impact of prior visceral leishmaniasis on subsequent malaria infection in mice.** 2021.  
<http://www.doi.org/10.17605/OSF.IO/DSVCP>
25. Forrester S, Siefert K, Ashwin H, *et al.*: **Tissue-specific transcriptomic changes associated with AmBisome® treatment of BALB/c mice with experimental visceral leishmaniasis [version 1; peer review: 3 approved].** *Wellcome Open Res.* 2019; **4**: 198.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
26. Rani GF, Preham O, Ashwin H, *et al.*: **Dissecting pathways to thrombocytopenia in a mouse model of visceral leishmaniasis.** *Blood Adv.* 2021; **5**(6): 1627–37.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
27. Tobón-Castaño A, Mesa-Echeverry E, Miranda-Arboleda AF: **Leukogram Profile and Clinical Status in *vivax* and *falciparum* Malaria Patients from Colombia.** *J Trop Med.* 2015; **2015**: 796182.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
28. Kotepui M, Piwkham D, PhunPhuech B, *et al.*: **Effects of Malaria Parasite Density on Blood Cell Parameters.** *PLoS One.* 2015; **10**(3): e0121057.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
29. Engwerda CR, Kaye PM: **Organ-specific immune responses associated with infectious disease.** *Immunol Today.* 2000; **21**(2): 73–8.  
[PubMed Abstract](#) | [Publisher Full Text](#)
30. WHO: **WHO This year's World malaria report at a glance.** Who. Global and regional malaria burden, in numbers. 2019; 1–10.  
[Reference Source](#)
31. WHO: **Leishmaniasis fact sheet.** WHO. 2020; [cited 2020 Oct 9].  
[Reference Source](#)
32. van den Bogaart E, Berkhout MMZ, Adams ER, *et al.*: **Prevalence, features and risk factors for malaria co-infections amongst visceral leishmaniasis patients from Amudat Hospital, Uganda.** *PLoS Negl Trop Dis.* 2012; **6**(4): e1617.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
33. Ghimire PG, Ghimire P, Adhikari J, *et al.*: **A case report of visceral leishmaniasis and malaria co-infection with pancytopenia and splenomegaly - a diagnostic challenge.** *BMC Infect Dis.* 2019; **19**(1): 849.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
34. Abongomera C, Diro E, Vogt F, *et al.*: **The Risk and Predictors of Visceral Leishmaniasis Relapse in Human Immunodeficiency Virus-Coinfected Patients in Ethiopia: A Retrospective Cohort Study.** *Clin Infect Dis.* 2017; **65**(10): 1703–10.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
35. Lindoso JAL, Moreira CHV, Cunha MA, *et al.*: **Visceral leishmaniasis and HIV coinfection: current perspectives.** *HIV AIDS (Auckl).* 2018; **10**: 193–201.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
36. van Rooijen N, Kors N, Kraal G: **Macrophage Subset Repopulation in the Spleen: Differential Kinetics After Liposome-Mediated Elimination.** *J Leukoc Biol.* 1989; **45**(2): 97–104.  
[PubMed Abstract](#) | [Publisher Full Text](#)
37. Beattie L, Engwerda CR, Wykes M, *et al.*: **CD8<sup>+</sup> T lymphocyte-mediated loss of marginal metallophilic macrophages following infection with *Plasmodium chabaudi* AS.** *J Immunol.* 2006; **177**(4): 2518–26.  
[PubMed Abstract](#) | [Publisher Full Text](#)
38. Netea MG, Joosten LAB, Latz E, *et al.*: **Trained immunity: A program of innate immune memory in health and disease.** *Science.* 2016; **352**(6284): aaf1098.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
39. Arneth B: **Trained innate immunity.** *Immunol Res.* 2021; **69**(1): 1–7.  
[PubMed Abstract](#) | [Publisher Full Text](#)
40. Mitroulis I, Hajishengallis G, Chavakis T: **Trained Immunity and Cardiometabolic Disease: The Role of Bone Marrow.** *Arterioscler Thromb Vasc Biol.* 2021; **41**(1): 48–54.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
41. Fanucchi S, Domínguez-Andrés J, Joosten LAB, *et al.*: **The Intersection of Epigenetics and Metabolism in Trained Immunity.** *Immunity.* 2021; **54**(1): 32–43.  
[PubMed Abstract](#) | [Publisher Full Text](#)
42. Engwerda CR, Beattie L, Amante FH: **The importance of the spleen in malaria.** *Trends Parasitol.* 2005; **21**(2): 75–80.  
[PubMed Abstract](#) | [Publisher Full Text](#)
43. Spence PJ, Jarra W, Lévy P, *et al.*: **Vector transmission regulates immune control of *Plasmodium* virulence.** *Nature.* 2013; **498**(7453): 228–31.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
44. Spence PJ, Jarra W, Lévy P, *et al.*: **Mosquito transmission of the rodent malaria parasite *Plasmodium chabaudi*.** *Malar J.* 2012; **11**: 407.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
45. Lucero E, Collin SM, Gomes S, *et al.*: **Effectiveness and safety of short course liposomal amphotericin B (AmBisome) as first line treatment for visceral leishmaniasis in Bangladesh.** *PLoS Negl Trop Dis.* 2015; **9**(4): e0003699.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
46. Belehu A, Poulter LW, Turk JL: **Influence of rodent malaria on the course of *Leishmania enriettii* infection of hamsters.** *Infect Immun.* 1976; **14**(2): 457–462.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

# Open Peer Review

Current Peer Review Status:  

---

## Version 2

Reviewer Report 09 July 2021

<https://doi.org/10.21956/wellcomeopenres.18750.r44578>

© 2021 Goto Y. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.



**Yasuyuki Goto** 

Laboratory of Molecular Immunology, Graduate School of Agricultural and Life Sciences, The University of Tokyo, Tokyo, Japan

The authors have well responded to my comments and made enough modifications.

**Competing Interests:** No competing interests were disclosed.

**Reviewer Expertise:** leishmaniasis

**I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.**

---

## Version 1

Reviewer Report 05 May 2021

<https://doi.org/10.21956/wellcomeopenres.18333.r43545>

© 2021 Scorza B. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.



**Breanna M. Scorza** 

Department of Epidemiology, University of Iowa, Iowa City, IA, USA

**Summary:**

Polyparasitism between Visceral Leishmaniasis (VL) and Malaria is well documented and occurs at varying rates across endemic areas. The authors note that studying diseases in the context of how

they might occur in naturally affected populations is critical to translational research and often experimental models are overly simplistic compared to the natural infection setting. For example, recent research has shown that previous pathogen experience can alter immune responses to subsequent heterologous infections by modulating the microenvironment. Here the authors establish a mouse model system to test the effect of previous VL and treatment on subsequent Malaria disease.

VL is established with a high dose of i.v. parasites, allowed to progress for 28 days, followed by treatment with AmbiSome, a frontline VL drug. The VL disease measurements have almost entirely returned to baseline 4wks post treatment. Four weeks post treatment, Malaria is initiated through iRBCs with rodent adapted plasmodium. Plasmodium parasitemia and disease severity are slightly delayed in the treated VL mice, however, no change increasing or decreasing response is observed. A weakness of the model is initiating malaria using blood stage parasites and bypassing the liver stage of infection, which may very well be affected by previous VL at this bottleneck. The authors conclude that VL in this model system did not change the immune environment sufficiently to affect malaria outcomes however, they acknowledge that their system is again perhaps too simplistic. Mice do not experience full VL disease compared to humans, dogs, or hamsters. They suggest longitudinal human studies in endemic areas as the best system to assess this complex pathogen ecology question.

The experimental model is well designed and presented. The system could use more technical replicates; however, the results seem to be quite clear even with the small number of mice at the later timepoints. The parameters used to assess VL or malaria disease are appropriate and give a good clinical picture. This study will be important for researchers studying coinfections or interactions between these parasitic diseases and should be published so as not to be repeated exactly. I agree with the authors that the findings presented here may well be different in a human study, where more chronic VL usually occurs and more long-lasting changes to the splenic architecture and bone marrow compartment may be experienced leading to different outcomes on subsequent infection. Human VL is also usually associated with malnutrition and lower socioeconomic standing, which could affect the immune microenvironment in itself.

**Minor comments:**

The authors did not address any adaptive immune functions in this model. Based off the clinical outcomes not significantly varying, I would assume the malaria adaptive response developed normally however one of the tenets underlying the reasoning for performing this study is that downstream effects may occur on subsequent infections. I wonder if the authors could speculate on whether the formation of immune memory or a secondary Malaria challenge would look like.

In the immunofluorescence images, the magenta SIGNR1 signal is very hard to discern apart from the red F4/80. In the future, white, yellow, or another color should be used to delineate these markers. Since the quantification is present, it does not prevent the reader from interpreting the results.

**Is the work clearly and accurately presented and does it cite the current literature?**

Yes

**Is the study design appropriate and is the work technically sound?**



Yes

**Are sufficient details of methods and analysis provided to allow replication by others?**

Yes

**If applicable, is the statistical analysis and its interpretation appropriate?**

Yes

**Are all the source data underlying the results available to ensure full reproducibility?**

Yes

**Are the conclusions drawn adequately supported by the results?**

Yes

**Competing Interests:** No competing interests were disclosed.

**Reviewer Expertise:** Leishmaniasis, immunology, host pathogen interactions, parasitology

**I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.**

Author Response 08 Jun 2021

**Paul Kaye**, University of York, UK, York, UK

We thank the reviewer for her supportive comments. We did not measure acquired immune responses to Plasmodium infection, but as the reviewer points out, we would not expect there to be major changes besides perhaps a delay in kinetics. We would prefer not to speculate on whether previous VL might impact memory generated during primary *Plasmodium* infection, but in our revised manuscript we have noted this as a possible area for further study (Discussion, paragraph 5).

**Competing Interests:** No competing interests were disclosed.

Reviewer Report 04 May 2021

<https://doi.org/10.21956/wellcomeopenres.18333.r43552>

© 2021 Goto Y. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.



**Yasuyuki Goto** 

Laboratory of Molecular Immunology, Graduate School of Agricultural and Life Sciences, The University of Tokyo, Tokyo, Japan

Due to a huge geographical overlap of VL and malaria, it is important to study how infection of one parasite affects infection with the other. Rani *et al.* further the topic by addressing the influence of past chemotherapy for VL to the subsequent *P. chabaudi* infection. Though a difference in the day of peak parasitemia was observed between VL-naïve and VL-treated mice upon *P. chabaudi* infection, no other major differences were found, suggesting that recovery from VL has limited impact on malaria pathology.

The paper is well written and the data shown here are sufficient to draw the presented conclusions. Additionally, discussions on the limitations of the study, including the infection route of *P. chabaudi*, un-sustained pathology of VL in the used mouse model and only one time point of post-treatment tested for influence to the subsequent infection, are fair.

However, the motivation for studying the influence of recovery from VL to malaria is still weak, because it is not clear what situation, in reality, the authors tried to simulate by this model. The timing of Plasmodium infection was 4 weeks after AmBisome treatment when splenomegaly still remained. This means the model would not reflect what happens in malaria on the majority of people with VL history. Though the authors discussed the limitation of testing only one post-treatment time point in this study, more careful discussions on what this model would reflect in a real situation are encouraged. The authors mentioned residual splenomegaly after treatment as a risk factor, which is just an indicator of incomplete treatment of VL which brings a higher chance of VL relapse and is irrelevant to the study objective which addresses the influence on other infections. Besides discussions on trained immunity, any chances for T/B cell cross reactivity between Leishmania and Plasmodium? This kind of discussion would be helpful to deliver the significance of why influence between Leishmania and Plasmodium was studied at the selected time point.

Please describe the total number of repeated experiments in M&M.

Figure 2B and elsewhere: Some data are pooled from two independent experiments, but why? The number of animals per group does not seem increased (n=3 for uninfected controls) even by pooling.

Figure 6E: Why (i) C and (ii) VT look so different? They should look similar according to Figure 2. Besides, the resolution of the images is low. Images with better quality should be posted as extended data if there is a space limit in the main text.

Other minor comments:

- Page 3 and elsewhere: Infection with malaria/malaria infection is better modified to infection with *Plasmodium/Plasmodium* infection.
- Page 3 and elsewhere: p.i to p.i.
- Page 3: About the sentence of 'Mice were kept...' in the paragraph of malaria infection on Procedures of M&M, I believe the 12-hour cycle is applied to all the mice even those without infection, correct? If different, please describe the light/dark cycle taken for non-infected mice.

- Page 5: No need to repeat the detail on F4/80 AF647 in M&M.
- Page 5: DAPI; 1 µg/ml: need space between the number and the unit.
- Page 8: 'In comparison to VT mice, ...' This does not make sense. VU should be 'untreated'.
- Page 9/Figure 5A: 'Delayed onset of thrombocytopenia after *P. chabaudi* infection and early recovery of platelet count...' Not sure if the data show 'early recovery'.
- Figure 1: i.v to i.v.
- Figure 4C: Not % BW 'loss', just % BW.
- Figure 4F: Are LDUs of VU at this time point supposed to be that low in both the spleen and liver?

**Is the work clearly and accurately presented and does it cite the current literature?**

Yes

**Is the study design appropriate and is the work technically sound?**

Yes

**Are sufficient details of methods and analysis provided to allow replication by others?**

Yes

**If applicable, is the statistical analysis and its interpretation appropriate?**

I cannot comment. A qualified statistician is required.

**Are all the source data underlying the results available to ensure full reproducibility?**

Partly

**Are the conclusions drawn adequately supported by the results?**

Yes

**Competing Interests:** No competing interests were disclosed.

**Reviewer Expertise:** leishmaniasis

**I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.**

Author Response 14 Jun 2021

**Paul Kaye**, University of York, UK, York, UK

We thank the reviewer for his detailed critique and have improved the manuscript by

addressing these as follows:

*.....This means the model would not reflect what happens in malaria on the majority of people with VL history.....The authors mentioned residual splenomegaly after treatment as a risk factor, which is just an indicator of incomplete treatment of VL which brings a higher chance of VL relapse and is irrelevant to the study objective which addresses the influence on other infections.* We did not intend to imply that there was evidence that residual splenomegaly was a risk factor for malaria, as this was the hypothesis under test in this study. We have now clarified this point (new text: Introduction paragraph 2). We agree with the reviewer that a majority of people with malaria following VL treatment are likely to have acquired their malaria at later times post treatment than modelled here. However, in areas of high malaria endemicity, exposure to *Plasmodium* could readily occur post discharge and before a return to full immune and / or hematological homeostasis. Hence, we believe that this model does reflect possible patient experience. However, we have amended the discussion to reflect the reviewer's comments (new text: Discussion paragraph 6).

*.....any chances for T/B cell cross reactivity between Leishmania and Plasmodium? This kind of discussion would be helpful to deliver the significance of why influence between Leishmania and Plasmodium was studied at the selected time point.*

We have not examined potential cross reactivity at the T or B cell level and thank the reviewer for highlighting this alternate possibility which we have now alluded to in the discussion (new text: Discussion paragraph 4).

*Please describe the total number of repeated experiments in M&M.*

Two independent experiments involving single *L. donovani* infection followed by drug treatment were performed. A single sequential infection experiment was performed. We have now added this information to the M&M.

*Figure 2B and elsewhere: Some data are pooled from two independent experiments, but why? The number of animals per group does not seem increased (n=3 for uninfected controls) even by pooling.*

In Figure 2B and 3B, the data were amalgamated not pooled from two experiments, and we apologise for this error. We conducted two experiments, but for logistical reasons and due to some technical difficulties, the time course was best represented by amalgamating the data, as now described more clearly in the figure legends (new text: Figure 2 and 3 legends).

*Figure 6E: Why (i) C and (ii) VT look so different? They should look similar according to Figure 2. Besides, the resolution of the images is low. Images with better quality should be posted as extended data if there is a space limit in the main text.*

We do not have a good explanation for the apparent differences in staining between control uninfected C mice and VT mice that have been rested for 7 weeks post treatment. It is possible that this reflects a change in architecture associated with Ambisome treatment that is evident at 7 weeks but not at 4 weeks post Rx, but we feel this is unlikely. More likely, it just reflects differences in sectioning or staining across different mouse groups (though it was a consistent finding in this mouse group). Similarly to Figure 2, these data do however show that whereas both control and VT mice have no evidence of granulomas, these are readily apparent in VU mice (though in less abundance than mice shown in Figure 2 due to



the extended time post infection). Unfortunately we do not have higher resolution images of these sections, but feel that the main message can be conveyed from those currently provided.

Other minor comments:

*Page 3 and elsewhere: Infection with malaria/malaria infection is better modified to infection with Plasmodium/Plasmodium infection*

We are happy with the reviewer's suggestion and have made this change throughout.

*Page 3 and elsewhere: p.i to p.i.*

We have corrected this throughout

*Page 3: About the sentence of 'Mice were kept...' in the paragraph of malaria infection on Procedures of M&M, I believe the 12-hour cycle is applied to all the mice even those without infection, correct? If different, please describe the light/dark cycle taken for non-infected mice.*

The reviewer is correct and we have made this clearer in the text

*Page 5: No need to repeat the detail on F4/80 AF647 in M&M.*

This repetition has been deleted

*Page 5: DAPI; 1µg/ml: need space between the number and the unit.*

Thank you. This has been corrected.

*Page 8: In comparison to VT mice, ...' This does not make sense. VU should be 'untreated'.*

This sentence has been re-worded to address this error.

*Page 9/Figure 5A: 'Delayed onset of thrombocytopenia after P. chabaudi infection and early recovery of platelet count...' Not sure if the data show 'early recovery'.*

We agree and have modified the sentence to only refer to the delayed onset

*Figure 1: i.v to i.v.*

We have corrected this throughout

*Figure 4C: Not % BW 'loss', just % BW.*

We have corrected this in the figure legend and provided a new Figure.

*Figure 4F: Are LDUs of VU at this time point supposed to be that low in both the spleen and liver?*  
By 11 weeks post infection (as in Figure 4F) liver parasite burdens in this mouse strain would be expected to be minimal. The splenic parasite loads are higher, albeit slightly lower than seen in some of our previous studies, but still reflects the poorer ability of this organ to clear primary infection. The related text as written was slightly confused, so we have re-written that for clarity.

**Competing Interests:** None